Peter Houghton

550 total citations
20 papers, 400 citations indexed

About

Peter Houghton is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Houghton has authored 20 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Houghton's work include Sarcoma Diagnosis and Treatment (5 papers), Neuroblastoma Research and Treatments (4 papers) and Cancer Research and Treatments (3 papers). Peter Houghton is often cited by papers focused on Sarcoma Diagnosis and Treatment (5 papers), Neuroblastoma Research and Treatments (4 papers) and Cancer Research and Treatments (3 papers). Peter Houghton collaborates with scholars based in United States, China and Australia. Peter Houghton's co-authors include Peter Dias, Juan Rosaí, David N. Shapiro, David M. Parham, Marcin Wysoczynski, Ryan Reca, Mariusz Z. Ratajczak, Dongling Zhao, Kacper Jankowski and Magda Kucia and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Peter Houghton

19 papers receiving 392 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Houghton United States	8	171	165	150	76	53	20	400
Corrado Gallo Stampino Italy	12	183 1.1×	103 0.6×	238 1.6×	58 0.8×	32 0.6×	31	419
Emily K. Slotkin United States	13	230 1.3×	271 1.6×	213 1.4×	135 1.8×	80 1.5×	38	548
Danmei Pang China	7	117 0.7×	151 0.9×	196 1.3×	113 1.5×	43 0.8×	17	357
Jürgen Stahl Australia	10	216 1.3×	85 0.5×	87 0.6×	75 1.0×	40 0.8×	20	364
Greg Friberg United States	10	259 1.5×	116 0.7×	189 1.3×	95 1.3×	59 1.1×	15	488
Karin Tyburski United States	6	230 1.3×	97 0.6×	291 1.9×	33 0.4×	99 1.9×	9	510
Aaron J. Schueneman United States	7	158 0.9×	109 0.7×	183 1.2×	89 1.2×	39 0.7×	8	377
Maksim Yezhelyev Germany	7	245 1.4×	61 0.4×	183 1.2×	56 0.7×	33 0.6×	7	429
Liam Cornell United States	5	210 1.2×	117 0.7×	181 1.2×	73 1.0×	19 0.4×	7	414
Roman Belousov United States	10	180 1.1×	194 1.2×	125 0.8×	63 0.8×	57 1.1×	10	413

Countries citing papers authored by Peter Houghton

Since Specialization

Citations

This map shows the geographic impact of Peter Houghton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Houghton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Houghton more than expected).

Fields of papers citing papers by Peter Houghton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Houghton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Houghton. The network helps show where Peter Houghton may publish in the future.

Co-authorship network of co-authors of Peter Houghton

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Houghton. A scholar is included among the top collaborators of Peter Houghton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Houghton. Peter Houghton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Chia-Chin, Zhenlin Ju, Xingzhi Song, et al.. (2024). Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models. Scientific Reports. 14(1). 19891–19891. 1 indexed citations

Yadav, Pooja, Panneerdoss Subbarayalu, Saif Nirzhor, et al.. (2022). M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression. Cancer Research. 82(10). 1872–1889. 59 indexed citations

Welliver, M.X., Pedro A. Torres‐Saavedra, Brian Andrew Van Tine, et al.. (2022). NRG-DT001 phase Ib trial of neoadjuvant navtemadlin (previously AMG232 and KRT232) concurrent with preoperative radiotherapy in wild-type p53 soft tissue sarcoma of the extremity and body wall.. Journal of Clinical Oncology. 40(16_suppl). 11521–11521. 1 indexed citations

Kurmasheva, Raushan T., Yaël P. Mossé, Eric J. Earley, et al.. (2021). Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC).. Journal of Clinical Oncology. 39(15_suppl). 10037–10037. 5 indexed citations

Horbinski, Craig, Guifa Xi, Yu‐Fen Wang, et al.. (2021). The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. Neuro-Oncology Advances. 3(1). vdab085–vdab085. 14 indexed citations

Yohe, Marielle E., Craig M. Goodwin, Terry J. Shackleford, et al.. (2021). Abstract LB251: Vertical inhibition of the RAF MEK ERK cascade induces myogenic differentiation, apoptosis and tumor regression in H/NRAS Q61X mutant rhabdomyosarcoma. Cancer Research. 81(13_Supplement). LB251–LB251. 1 indexed citations

Richardson, Jeffery, Kevin P. Cole, Amy C. DeBaillie, et al.. (2020). Development of a Scalable Synthesis of Mevidalen (LY3154207), an Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor. Organic Process Research & Development. 24(11). 2549–2564. 9 indexed citations

Gu, Xiang, Bingzhi Wang, Haiyan Zhu, et al.. (2020). Age-associated genes in human mammary gland drive human breast cancer progression. Breast Cancer Research. 22(1). 64–64. 21 indexed citations

Xia, Lu, Hakim Bouamar, Xiang Gu, et al.. (2020). Gli2 mediates the development of castration‑resistant prostate cancer. International Journal of Oncology. 57(1). 100–112. 13 indexed citations

10.

Welliver, M.X., Brian Andrew Van Tine, Peter Houghton, et al.. (2019). MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001).. Journal of Clinical Oncology. 37(15_suppl). TPS11076–TPS11076. 7 indexed citations

11.

Shackleford, Terry J., et al.. (2017). Abstract 5825: Mechanisms of intrinsic and acquired resistance to antibodies targeting IGF-1R in pediatric sarcoma cell lines. Cancer Research. 77(13_Supplement). 5825–5825. 1 indexed citations

12.

Smith, Matthew A., Min H. Kang, Richard B. Lock, et al.. (2014). 410 Pediatric Preclinical Testing Program (PPTP) Evaluation of the p53-MDM2 Antagonist MK-8242. European Journal of Cancer. 50. 131–131. 1 indexed citations

13.

Smith, Malcolm A., Min H. Kang, Richard Görlick, et al.. (2013). Abstract 2755: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of NSC750854, a sulfamated purine analog with a distinctive anticancer activity profile.. Cancer Research. 73(8_Supplement). 2755–2755. 1 indexed citations

14.

Smith, Malcolm A., Min H. Kang, Richard Görlick, et al.. (2013). Abstract C206: Pediatric Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ).. Molecular Cancer Therapeutics. 12(11_Supplement). C206–C206. 3 indexed citations

15.

Smith, Malcolm A., Min H. Kang, Richard Görlick, et al.. (2013). Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib.. Cancer Research. 73(8_Supplement). LB–353. 6 indexed citations

16.

Kang, Myoung Hee, Richard B. Lock, Hernán Carol, et al.. (2012). 345 Pediatric Preclinical Testing Program (PPTP) Stage 1 Evaluation of Eribulin. European Journal of Cancer. 48. 105–105.

17.

Lock, Richard B., Hernán Carol, Peter Houghton, et al.. (2008). 192 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the anti-CD19-DM4 conjugated antibody SAR3419. European Journal of Cancer Supplements. 6(12). 61–61. 1 indexed citations

18.

Rodríguez‐Galindo, Carlos, Kristine R. Crews, Clinton F. Stewart, et al.. (2005). Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 57(1). 15–24. 15 indexed citations

19.

Jankowski, Kacper, Magda Kucia, Marcin Wysoczynski, et al.. (2003). Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.. PubMed. 63(22). 7926–35. 156 indexed citations

20.

Rosaí, Juan, Peter Dias, David M. Parham, David N. Shapiro, & Peter Houghton. (1991). MyoDl Protein Expression in Alveolar Soft Part Sarcoma As Confirmatory Evidence of Its Skeletal Muscle Nature. The American Journal of Surgical Pathology. 15(10). 974–981. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact